VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.553
-0.024 (-4.13%)
At close: Feb 21, 2025, 4:00 PM
0.570
+0.017 (3.17%)
After-hours: Feb 21, 2025, 6:08 PM EST
VolitionRx Revenue
VolitionRx had revenue of $474.52K in the quarter ending September 30, 2024, with 187.22% growth. This brings the company's revenue in the last twelve months to $1.29M, up 97.50% year-over-year. In the year 2023, VolitionRx had annual revenue of $775.30K with 153.04% growth.
Revenue (ttm)
$1.29M
Revenue Growth
+97.50%
P/S Ratio
35.66
Revenue / Employee
$11,689
Employees
110
Market Cap
51.20M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | 17.10K | - | - |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
VNRX News
- 16 days ago - Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis - PRNewsWire
- 17 days ago - Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025 - PRNewsWire
- 23 days ago - Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis - PRNewsWire
- 6 weeks ago - Volition Issues Business Review 2024 - PRNewsWire
- 2 months ago - VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants - PRNewsWire
- 2 months ago - Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening - PRNewsWire
- 2 months ago - VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering - PRNewsWire
- 3 months ago - VolitionRx Limited (VNRX) Q3 2024 Earnings Call Transcript - Seeking Alpha